Abstract
The systemic treatment of superficial fungus infections in man at last seems a near reality. Although the polyene antibiotics derived from streptomyces were a significant advance in antifungal chemotherapy against the yeast-like fungi, they failed to influence the common dermatomycoses.<sup>1</sup>Recent studies demonstrating the influence of serum factors in superficial fungous infections illustrated the importance of blood-borne substances in confining cutaneous invasion by dermatophytes.<sup>2,15</sup>Gentles' recent report of the successful oral treatment of Trichophyton and Microsporum infections in guinea pigs with griseofulvin, a product of several penicillia, was a great step forward.<sup>7</sup>Subsequently, Lauder and O'Sullivan found it effective by mouth in calves with Trichophyton verrucosum infections.<sup>11</sup>Our paper is a preliminary report of observations on the effectiveness of oral griseofulvin therapy in man. Griseofulvin is a colorless, neutral, thermostable antibiotic isolated from Penicillium griseofulvin by Oxford, Raistrick, and Simonet,<sup>13</sup>in 1939. Interest in the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
